In-hospital outcomes of patients with antiphospholipid syndrome undergoing transcatheter and surgical aortic valve replacement: A population-based analysis of national inpatient sample from 2015–2021
Lupus · 2025
DOI: 10.1177/09612033251322012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lupus, 2025. Verfasst von Renxi Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Health Sciences, The George Washington University, Washington, D.C., USA. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Transcatheter Aortic Valve Replacement, Heart Valve Prosthesis Implantation, Aortic Valve Stenosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
Valvular abnormalities are common in antiphospholipid syndrome (APS). For patients who undergo aortic valve replacement (AVR), previous single institutional studies or case reports reported higher risks of mortality and thromboembolic complications among APS patients. This study aimed to investigate in-hospital outcomes of APS patients undergoing transcatheter (TAVR) and surgical aortic valve replacement (SAVR) using the largest all-payer database in the United States.
Methods
Patients who underwent TAVR and SAVR were selected from National Inpatient Sample from Q4 2015-2021. Exclusion criteria were age under 18 years and concomitant procedures. Preoperative characteristics were matched between APS and non-APA patients using a 1:5 propensity-score matching in TAVR and SAVR, separately. In-hospital outcomes were examined.
Results
After propensity-score matching, 504 non-APS patients were matched to 100 APS patients in TAVR, while 581 non-APS patients were matched to 119 APS patients in SAVR. All outcomes between APS and non-APS patients were comparable after TAVR. In contrast, APS patients undergoing SAVR had higher risks of pulmonary embolism (PE; 5.13% vs 0.86%, p < .01) and acute kidney injury (AKI; 35.04% vs 22.55%, p = .01).
Conclusion
This study represents one of the first large-scale, population-based analyses of AVR outcomes for APS patients using a national registry. APS patients had all comparable outcomes after TAVR, while they had higher risks of PE and AKI after SAVR. This highlights the necessity for close perioperative antithrombotic management and careful monitoring of renal function in APS patients. TAVR may offer a safer alternative to SAVR for appropriately selected patients, including those with APS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine and Health Sciences, The George Washington University, Washington, D.C., USA.
- Division of Cardiovascular and Thoracic Surgery, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN, USA.
ORCID-Profile: Renxi Li
Zitieren
APA
Li, R., & Huddleston, S. J. (2025). In-hospital outcomes of patients with antiphospholipid syndrome undergoing transcatheter and surgical aortic valve replacement: A population-based analysis of national inpatient sample from 2015–2021. Lupus. https://doi.org/10.1177/09612033251322012
Vancouver
Li R, Huddleston SJ. In-hospital outcomes of patients with antiphospholipid syndrome undergoing transcatheter and surgical aortic valve replacement: A population-based analysis of national inpatient sample from 2015–2021. Lupus. 2025. doi:10.1177/09612033251322012
BibTeX
@article{Li2025,
author = {Li, Renxi and Huddleston, Stephen J},
title = {In-hospital outcomes of patients with antiphospholipid syndrome undergoing transcatheter and surgical aortic valve replacement: A population-based analysis of national inpatient sample from 2015–2021},
journal = {Lupus},
year = {2025},
doi = {10.1177/09612033251322012}
}
EUVIMED